Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload

NCT01254227 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiac Iron Overload

Interventions

DRUG: Deferasirox and Deferoxamine

Sponsor

Novartis Pharmaceuticals